SCHEMBL609343

SCHEMBL609343

CCCCCN=Nc1ncccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
KDM4E B2RXH2 2/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
NPC1 O15118 1/20 0.36
HSP90AA1 P07900 1/20 0.36
RAB9A P51151 1/20 0.36
NOS1 P29475 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP2D6 P10635 1/20 0.32
CYP19A1 P11511 1/20 0.32
CYP2C9 P11712 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
TLR8 Q9NR97 2/20 0.31
KCNH2 Q12809 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609342 1.00 LMNA (0.36) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL16592821 0.78 LMNA (0.46) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL16592822 0.78 LMNA (0.46) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL11495779 0.74 LMNA (0.36) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL11495776 0.74 LMNA (0.36) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL10995648 0.74 HSD17B10 (0.41) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL10995652 0.74 HSD17B10 (0.41) LMNAKDM4EHTTSMN1; SMN2USP2
SCHEMBL4800682 0.72 L3MBTL1 (0.47) LMNAKDM4ESMN1; SMN2USP2ALOX15
SCHEMBL3432777 0.69 ALDH1A1 (0.44) HTTSMN1; SMN2NPC1RAB9ACYP1A2
SCHEMBL3432776 0.69 ALDH1A1 (0.44) HTTSMN1; SMN2NPC1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0052959-B1 PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR Takeda Chemical Industries, Ltd. (JP) 1986-01-29 EP claimed
EP-0052959-A1 Production of purine derivatives and intermediates therefor Takeda Chemical Industries, Ltd. (JP) 1982-06-02 EP claimed
JP-58032867-A None JP disclosed
EP-3224262-B1 NEW METAL N-AMINOGUANIDINATE COMPLEXES FOR USE IN THIN FILM FABRICATION AND CATALYSIS UMICORE AG & CO KG (DE) 2020-08-26 EP disclosed
US-10093687-B2 Metal N-aminoguanidinate complexes for use in thin film fabrication and catalysis UMICORE AG & CO. KG (DE) 2018-10-09 US disclosed
EP-3224262-A1 NEW METAL N-AMINOGUANIDINATE COMPLEXES FOR USE IN THIN FILM FABRICATION AND CATALYSIS Umicore AG & Co. KG (DE) 2017-10-04 EP disclosed
US-20170260213-A1 NEW METAL N-AMINOGUANIDINATE COMPLEXES FOR USE IN THIN FILM FABRICATION AND CATALYSIS UMICORE AG & CO. KG (DE) 2017-09-14 US disclosed
WO-2016083471-A1 NEW METAL N-AMINOGUANIDINATE COMPLEXES FOR USE IN THIN FILM FABRICATION AND CATALYSIS UMICORE AG & CO. KG (DE) 2016-06-02 WO disclosed
EP-3026055-A1 New metal N-aminoguanidinate complexes for use in thin film fabrication and catalysis Umicore AG & Co. KG (DE) 2016-06-01 EP disclosed
US-20120130058-A1 REDUCTION OF 5-(ARYL-DIAZENYL)-4,6-DIHALO-PYRIMIDINE QUITTMANN WILHELM (CH) 2012-05-24 US disclosed
US-8114996-B2 Reduction of 5-(aryl-diazenyl)-4,6-dihalo-pyrimidine LONZA AG (CH) 2012-02-14 US disclosed
US-5516905-A ENZYME INHIBITORS OF DNA POLYMERASE FOR BACTERICIDES UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) 1996-05-14 US disclosed
WO-1996006614-A1 NOVEL ANTIBIOTIC COMPOUNDS AND METHODS TO TREAT GRAM-POSITIVE BACTERIAL AND MYCOPLASMAL INFECTIONS UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER (US) 1996-03-07 WO disclosed
EP-0052959-B1 PRODUCTION OF PURINE DERIVATIVES AND INTERMEDIATES THEREFOR Takeda Chemical Industries, Ltd. (JP) 1986-01-29 EP disclosed
EP-0101273-A2 Production of biological products using resting cells THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1984-02-22 EP disclosed
US-4423219-A 6-/2-CHLORO-6-FLUOROBENZYL/AMINO-4-METHYLAMINO-5 -PHENYLAZOPYRIMIDINE, ANTIPROTOZOA TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1983-12-27 US disclosed
US-4423219-A 6-/2-CHLORO-6-FLUOROBENZYL/AMINO-4-METHYLAMINO-5 -PHENYLAZOPYRIMIDINE, ANTIPROTOZOA TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1983-12-27 US disclosed
JP-S5832867-A NOVEL ARYLAZOPYRIMIDINE COMPOUND TAKEDA CHEM IND LTD 1983-02-25 JP disclosed
EP-0052959-A1 Production of purine derivatives and intermediates therefor Takeda Chemical Industries, Ltd. (JP) 1982-06-02 EP disclosed
EP-0052959-A1 Production of purine derivatives and intermediates therefor Takeda Chemical Industries, Ltd. (JP) 1982-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260213-A1 NEW METAL N-AMINOGUANIDINATE COMPLEXES FOR USE IN THIN FILM FABRICATION AND CATALYSIS GNMT, NNMT, AOX1 LMNA 2410/4885KDM4E 1241/4885HTT 3905/4885
US-20120130058-A1 REDUCTION OF 5-(ARYL-DIAZENYL)-4,6-DIHALO-PYRIMIDINE PDXK, KHK, GCK LMNA 4657/4885KDM4E 2059/4885HTT 774/4885
US-10093687-B2 Metal N-aminoguanidinate complexes for use in thin film fabrication and catalysis AOC1, AMD1, AOC2 LMNA 2336/4885KDM4E 922/4885HTT 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.